Chronic Spontaneous Urticaria and Bruton Tyrosine Kinase: A Multispecialty Expert Discussion - Episode 12
Evolving Paradigm for CSU Treatment
Published on:
Panelists discuss how Bruton tyrosine kinase (BTK) inhibitors could transform chronic spontaneous urticaria (CSU) treatment by offering a targeted oral therapy option that works rapidly across both autoallergic and autoimmune subtypes, potentially providing an effective alternative before escalating to biologics or immunosuppressants.
Video content above is prompted by the following:
- If approved, how would BTK inhibitors change the treatment spectrum for patients with CSU?
